Dupixent (Dupilumab)

Centralized in June 2026 before Judge Zahid N. Quraishi in the District of New Jersey, the Dupixent (Dupilumab) litigation is one of the youngest active federal MDLs, with just 36 total actions filed and 35 still pending as of the JPML's September 2026 report — a docket barely three months old. Funding availability at this stage looks fundamentally different than in a mature mass tort: there is no bellwether track record, no general-causation ruling, and no settlement program to benchmark against, so any funding decision today rests almost entirely on the strength of an individual claimant's medical records and product-use history rather than on docket-wide outcome data.

For a law firm building out an early inventory of Dupixent claims, this is the phase where claim-sourcing discipline matters most: intake criteria, diagnosis documentation, and prescriber records set the foundation for how the book will be valued once the docket matures and a leadership structure, master complaint, and case-management order are in place. Portfolio finance against a young docket like this is available, but it is priced and structured differently than portfolio finance against a mature book — durations run longer, and the funder is underwriting the litigation's trajectory as much as any specific claim.

Medical-lien exposure should be tracked from the outset even at this early stage, since dupilumab is typically prescribed for chronic conditions with ongoing treatment histories, and any recovery will need to account for insurer and provider liens tied to that ongoing care. As the docket develops, Criterica Capital's mass tort finance product remains the relevant structure for claims and portfolios tied to this litigation, and a structural brief tracking the docket's early development is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.